Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 30,941 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $14.79, for a total value of $457,617.39. Following the completion of the sale, the chief operating officer owned 647,809 shares in the company, valued at $9,581,095.11. This represents a 4.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Julie Rubinstein also recently made the following trade(s):

• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.68, for a total transaction of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $15.67, for a total transaction of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.00, for a total transaction of $495,056.00.

Adaptive Biotechnologies Trading Down 2.9%

ADPT opened at $14.52 on Wednesday. Adaptive Biotechnologies Corporation has a 12 month low of $6.26 and a 12 month high of $20.76. The company has a market cap of $2.24 billion, a PE ratio of -36.30 and a beta of 2.19. The company has a 50 day moving average of $16.72 and a 200 day moving average of $15.88.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same quarter in the prior year, the business posted ($0.23) earnings per share. The business’s quarterly revenue was up 51.0% on a year-over-year basis. Research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on ADPT shares. JPMorgan Chase & Co. increased their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Finally, Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $18.25.

Hedge Funds Weigh In On Adaptive Biotechnologies

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC lifted its holdings in shares of Adaptive Biotechnologies by 3.4% during the 4th quarter. Corient Private Wealth LLC now owns 71,908 shares of the company’s stock worth $1,168,000 after acquiring an additional 2,347 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Adaptive Biotechnologies during the fourth quarter worth about $28,000. T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies in the 4th quarter worth about $51,000. Invesco Ltd. boosted its holdings in shares of Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after purchasing an additional 2,216,595 shares in the last quarter. Finally, Strive Financial Group LLC bought a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at about $52,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.